TBS in Major Depression

Treatment Resistant Depression Clinical Trial

Official title:

Theta-burst Transcranial Magnetic Stimulation for the Treatment of Major Depression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03257397
• Other study ID #: PSY-NIL-0008
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2017
• Est. completion date: December 31, 2020

Study information

• Verified date: March 2019
• Source: Medical University of Vienna
• Contact: Georg S Kranz, PhD
• Phone: +43 1 40400
• Email: georg.kranz[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background Major depression is associated with morbidity and increased mortality. Along with the psychological strain depression represents a high socioeconomic burden costing Europe more than €113 billion/year. About one third of patients do not respond to appropriate therapy. Theta-burst stimulation (TBS), a form of transcranial magnetic stimulation is an emerging treatment for patients for whom pharmacological treatment is ineffective or not appropriate. Based on two different theories of prefrontal dysfunction two TBS-protocols should have the most antidepressant effects. However, no study so far has compared the two approaches or systematically investigated their differential effects on brain function and on a symptom level.

Objectives of the study The aim of this study is to test two TBS protocols on symptom improvement and associated brain function in patients with treatment resistant depression (TRD): iTBS over bilateral DLPFC and iTBS over left and cTBS over right DLPFC. As stimulation over non-motor regions offers no direct readout, fMRI at baseline and after treatment will be harnessed to quantify an effect on brain activity and functional network metrics.

Study population 80 patients with TRD will be enrolled with 40 patients receiving the one, and 40 patients receiving the other TBS protocol for a treatment period of three weeks.

Study design The study is designed as a longitudinal, randomized and double-blind clinical trial. At baseline and after treatment, patients will undergo psychiatric testing using several symptom scales including the Hamilton Depression Rating Scale (HAMD-17), the Beck Depression Inventory (BDI-II), the Inventory of Depressive Symptomatology (IDS-C) and the State-Trait Anxiety Inventory (STAI). Changes in HAMD-17 scores are defined as primary endpoint. Moreover MRI scans before and after treatment will include structural and functional MRI sequences as well as diffusion weighted imaging (DWI) sequence. Functional connectivity and BOLD responses will serve as primary imaging endpoints. A follow-up visit 2 weeks and a final examination 4 weeks after treatment will elucidate durability of effects.

Relevance and implications of the study By investigating which approach is superior for which symptoms our study will contribute to the development of personalized treatment, the reduction of personal suffering and the reduction of costs and occupational disability.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 31, 2020
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• DSM-5 diagnosis of a single or recurrent major depression

• Failure of at least two adequate antidepressant treatments

• HAMD-17 total score of = 23 and a Clinical Global Impression Scale (CGI-S) of = 4

• Stable psychopharmacological treatment within 2 weeks prior inclusion

• Age 18-65 years

• Right-handedness (assessed with the Edinburgh Handedness Inventory)

Exclusion Criteria:

• Seizures in medical history

• Medical history of major systemic illness, neurological disorders and previous brain injuries

• Ferromagnetic implants, cardiac pacemaker, deep brain stimulation and other common MRI and TMS exclusion criteria

• Current psychotic symptoms

• Substance abuse or dependence within last 3 months

• Borderline personality disorder (based on DSM-5 criteria)

• Pregnancy

• Active suicidal intent

• Benzodiazepines other than Lorazepam < 2mg/d

• failure to comply with the study protocol or to follow the instructions of the investigating team

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Depressive Disorder, Treatment-Resistant
• Treatment Resistant Depression

Intervention

Device:
• theta-burst stimulation (TBS) using a MagPro X1000
iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
• theta-burst stimulation (TBS) using a MagPro X1000
iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions

Locations

Country	Name	City	State
Austria	Department of Psychiatry and Psychotherapy, Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Rupert Lanzenberger

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Global physical activity	assessed using Clinical Global Impression Scale (CGI-S)	<1 month
Primary	HAMD	Hamilton depression rating scale	<1 month
Primary	BDI-II	Beck Depression Inventory	<1 month
Secondary	Regional white matter microstructure using DWI	White matter microstructure will be investigated using diffusion tensor imaging and analyzed using tract-based spatial statistics and tractography	<1 month
Secondary	Regional grey matter volume and using MRI	Regional grey matter volume will be investigated using voxel-based morphometry	<1 month